Ipriflavone: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)
 
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Protected "Ipriflavone": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457127710
| IUPAC_name = 7-isopropoxy-3-phenyl-4''H''-chromen-4-one
| image = ipriflavone.png
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|ipriflavone}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = 
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 35212-22-7
| ATC_prefix = M05
| ATC_suffix = BX01
| PubChem = 3747
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 80BJ7WN25Z
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01338
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 165790
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 3616




{{Drugbox
<!--Chemical data-->
| IUPAC_name        = 3-phenyl-7-propan-2-yloxychromen-4-one
| C=18 | H=16 | O=3  
| image            = ipriflavone.png
| molecular_weight = 280.318 g/mol
| CAS_number        =
| synonyms = <small>3-phenyl-7-propan-2-yloxychromen-4-one</small>
| ATC_prefix        =
| smiles            = CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3
| ATC_suffix        =
| InChI            = 1/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3
| PubChem          = 3747
| InChIKey          = SFBODOKJTYAUCM-UHFFFAOYAK
| DrugBank          =
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| C=18|H=16|O=3
| StdInChI         = 1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3
| molecular_weight = 280.318 g/mol
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| bioavailability  =  
| StdInChIKey      = SFBODOKJTYAUCM-UHFFFAOYSA-N
| protein_bound    =  
| metabolism        =  
| elimination_half-life =  
| excretion        =  
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category=
| legal_AU         = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA          =  <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK          =  <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US          =  <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status      =  
| routes_of_administration =  
}}
}}
              __NOTOC__
{{SI}}
{{SI}}
'''Ipriflavone''' is a synthetic [[isoflavone]] which is used to maintain bone density and to prevent [[osteoporosis]] in postmenopausal women. It is not used to treat osteoporosis. It slows down the action of the [[osteoclast]]s (bone-eroding cells), allowing the [[osteoblast]]s (bone-building cells) to build up bone mass.
{{CMG}}
==Overview==
 
'''Ipriflavone''' is a synthetic [[isoflavone]] which may be used to inhibit bone resorption,<ref name="pmid9263610">{{cite journal |doi=10.1007/s002239900378 |title=In Vitro and in Vivo effects of ipriflavone on bone formation and bone biomechanics |year=1997 |last1=Civitelli |first1=R. |journal=Calcified Tissue International |volume=61 |pages=S12–4 |pmid=9263610}}</ref> maintain bone density and to prevent [[osteoporosis]] in postmenopausal women. It is not used to treat osteoporosis. It slows down the action of the [[osteoclast]]s (bone-eroding cells), possibly allowing the [[osteoblast]]s (bone-building cells) to build up bone mass.
 
A clinical trial reported in 2001 that it was ''not'' effective in prevention or treatment of osteoporosis.<ref>{{cite journal |pages=1482–8 |doi=10.1001/jama.285.11.1482 |title=Ipriflavone in the Treatment of Postmenopausal Osteoporosis: A Randomized Controlled Trial |year=2001 |last1=Alexandersen |first1=P. |journal=JAMA |volume=285 |issue=11 |pmid=11255425 |last2=Toussaint |first2=A |last3=Christiansen |first3=C |last4=Devogelaer |first4=JP |last5=Roux |first5=C |last6=Fechtenbaum |first6=J |last7=Gennari |first7=C |last8=Reginster |first8=JY |author9=Ipriflavone Multicenter European Fracture Study }}</ref>
 
A double-blind study reveals that ipriflavone might be effective on reducing tinnitus on [[otosclerosis]] sufferers.<ref>{{cite journal |pmid=1343452 |year=1992 |last1=Sziklai |first1=I |last2=Komora |first2=V |last3=Ribári |first3=O |title=Double-blind study on the effectiveness of a bioflavonoid in the control of tinnitus in otosclerosis |volume=33 |issue=1–2 |pages=101–7 |journal=Acta chirurgica Hungarica}}</ref>
 
==References==
{{Reflist|2}}


==External links==
==External links==
*[http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/ipr_0147.shtml Ipriflavone] at PDR Health
*[http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/ipr_0147.shtml Ipriflavone] at PDR Health


[[Category:Flavonoids]]
{{Drugs for treatment of bone diseases}}
{{Bisphosphonates}}
 
[[Category:Endocrinology]]


{{WikiDoc Help Menu}}
[[Category:Drug]]
{{WikiDoc Sources}}
[[Category:Phenol ethers]]

Latest revision as of 16:32, 20 August 2015

Ipriflavone
Clinical data
Synonyms3-phenyl-7-propan-2-yloxychromen-4-one
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC18H16O3
Molar mass280.318 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Ipriflavone

Articles

Most recent articles on Ipriflavone

Most cited articles on Ipriflavone

Review articles on Ipriflavone

Articles on Ipriflavone in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ipriflavone

Images of Ipriflavone

Photos of Ipriflavone

Podcasts & MP3s on Ipriflavone

Videos on Ipriflavone

Evidence Based Medicine

Cochrane Collaboration on Ipriflavone

Bandolier on Ipriflavone

TRIP on Ipriflavone

Clinical Trials

Ongoing Trials on Ipriflavone at Clinical Trials.gov

Trial results on Ipriflavone

Clinical Trials on Ipriflavone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ipriflavone

NICE Guidance on Ipriflavone

NHS PRODIGY Guidance

FDA on Ipriflavone

CDC on Ipriflavone

Books

Books on Ipriflavone

News

Ipriflavone in the news

Be alerted to news on Ipriflavone

News trends on Ipriflavone

Commentary

Blogs on Ipriflavone

Definitions

Definitions of Ipriflavone

Patient Resources / Community

Patient resources on Ipriflavone

Discussion groups on Ipriflavone

Patient Handouts on Ipriflavone

Directions to Hospitals Treating Ipriflavone

Risk calculators and risk factors for Ipriflavone

Healthcare Provider Resources

Symptoms of Ipriflavone

Causes & Risk Factors for Ipriflavone

Diagnostic studies for Ipriflavone

Treatment of Ipriflavone

Continuing Medical Education (CME)

CME Programs on Ipriflavone

International

Ipriflavone en Espanol

Ipriflavone en Francais

Business

Ipriflavone in the Marketplace

Patents on Ipriflavone

Experimental / Informatics

List of terms related to Ipriflavone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ipriflavone is a synthetic isoflavone which may be used to inhibit bone resorption,[1] maintain bone density and to prevent osteoporosis in postmenopausal women. It is not used to treat osteoporosis. It slows down the action of the osteoclasts (bone-eroding cells), possibly allowing the osteoblasts (bone-building cells) to build up bone mass.

A clinical trial reported in 2001 that it was not effective in prevention or treatment of osteoporosis.[2]

A double-blind study reveals that ipriflavone might be effective on reducing tinnitus on otosclerosis sufferers.[3]

References

  1. ↑ Civitelli, R. (1997). "In Vitro and in Vivo effects of ipriflavone on bone formation and bone biomechanics". Calcified Tissue International. 61: S12–4. doi:10.1007/s002239900378. PMID 9263610.
  2. ↑ Alexandersen, P.; Toussaint, A; Christiansen, C; Devogelaer, JP; Roux, C; Fechtenbaum, J; Gennari, C; Reginster, JY; Ipriflavone Multicenter European Fracture Study (2001). "Ipriflavone in the Treatment of Postmenopausal Osteoporosis: A Randomized Controlled Trial". JAMA. 285 (11): 1482–8. doi:10.1001/jama.285.11.1482. PMID 11255425.
  3. ↑ Sziklai, I; Komora, V; Ribári, O (1992). "Double-blind study on the effectiveness of a bioflavonoid in the control of tinnitus in otosclerosis". Acta chirurgica Hungarica. 33 (1–2): 101–7. PMID 1343452.

External links

Template:Drugs for treatment of bone diseases

Retrieved from "https://www.wikidoc.org/index.php?title=Ipriflavone&oldid=1136854"